Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Immunotherapy
  • Neoplasm Proteins
  • Tumor Microenvironment

abstract

  • Large-scale genomic kidney cancer studies reported novel mutations and heterogeneous features among individual tumors, which could contribute to varied clinical outcomes. We demonstrated correlations between somatic mutations and treatment outcomes in clear cell renal cell carcinoma, supporting the value of genomic classification in prospective studies.

publication date

  • March 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5431298

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2016.10.007

PubMed ID

  • 27751729

Additional Document Info

start page

  • 405

end page

  • 414

volume

  • 71

number

  • 3